GE HealthCare announced on April 16, 2026 that it is expanding its collaboration with DeepHealth, a subsidiary of RadNet, to extend global access to DeepHealth’s AI‑powered breast cancer screening solutions.
The expanded partnership builds on a joint initiative first announced in 2024, which combined DeepHealth’s AI workflow with GE HealthCare’s Senographe Pristina™ mammography system to improve image interpretation and operational efficiency. The new phase adds a second‑reader workflow and broadens availability of DeepHealth’s Breast Suite applications worldwide.
DeepHealth’s Breast Suite has been shown to increase breast cancer detection rates by 21.6% overall and by 22.7% for women with dense breasts, according to a study published in Nature Health. By integrating the Breast Suite AI with the Pristina Via™ system, GE HealthCare aims to raise detection confidence, streamline clinical workflows, and position the company to capture a larger share of the expanding AI‑driven diagnostic market.
GE HealthCare’s Q4 2025 results, released on February 4, 2026, showed revenue of $5.7 billion, up 7.1% year‑over‑year, and an adjusted EBIT margin of 16.7%. The strong performance underpins GE HealthCare’s continued investment in AI partnerships. DeepHealth launched its comprehensive Breast Suite in December 2025, adding to its portfolio of AI‑enabled health informatics solutions.
"At GE HealthCare, we're advancing women's health through precision care built around the unique needs of women and enhanced by the power of AI. By integrating Breast Suite AI with our Pristina Via™ mammography system, we're helping clinicians detect breast cancer early with greater confidence. These innovations move us closer towards truly personalized prevention and care for women.” – Jyoti Gupta, PhD, President and CEO, Women's Health and X‑ray at GE HealthCare.
"At DeepHealth, we are committed to bringing the next era of AI‑powered health informatics to help stage shift disease. Through our expanded collaboration with GE HealthCare, we are bringing the power of our new Breast Suite to providers around the world to enable early cancer detection, deeper clinical insights, and more confident decisions. Together we are pushing the boundaries of what mammography can deliver, not only for breast cancer screening but for women's health more broadly.” – Niccolo Stefani, MD, Business Leader Population Health & Clinical AI, DeepHealth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.